2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2758

Quantifying The Risk Of Incident Type II Diabetes Following Oral Glucocorticoid Therapy In Patients With Rheumatoid Arthritis: Association With Dose and Duration Of Use
Abstract Number: 890

Quantitative Cell Distance Mapping In Human Nephritis Reveals Organization Of In Situ Adaptive Immune Responses
Abstract Number: 1964

Quantitative Erosion Volume Measurement From Computed Tomography
Abstract Number: 227

Quantitative Image Analysis Of Articular Involvement In Blau Syndrome By Radiographic Calpal Length and Ultrasound Assessment
Abstract Number: 1069

Racial Differences In Systemic Lupus Erythematosus Patients’ Treatment Preferences: A Two-Site Study
Abstract Number: 1996

Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Abstract Number: 2469

Radiographic Sacroiliitis Progression In An Early Spondyloarthritis Cohort
Abstract Number: 2804

Radiological Outcome Of Joints With MRI Detected Subclinical Inflammation In Early Arthritis Patients
Abstract Number: 143

Rapid Infrared Microscopy (IRMS) For Differential Diagnosis Of Fibromyalgia and Other Central Sensitivity Syndromes
Abstract Number: 2535

Rare Autoantibodies To Cellular Antigens In Systemic Lupus Erythematosous
Abstract Number: 745

Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Abstract Number: 282

Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy
Abstract Number: 1047

Rates Of Hospitalized Infections In Rheumatoid Arthritis Patients From 5 Rheumatoid Arthritis Registries Across The World
Abstract Number: 782

Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World
Abstract Number: 1458

Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].